| Version | Summary | Created by | Modification | Content Size | Created at | Operation |
|---|---|---|---|---|---|---|
| 1 | Yu Peng | -- | 175 | 2026-11-15 16:32:59 | | | |
| 2 | Yu Peng | -13 word(s) | 162 | 2026-11-15 16:35:05 | | | | |
| 3 | Catherine Yang | Meta information modification | 162 | 2026-11-16 03:59:12 | | |
A tyrosine kinase inhibitor is a compound that suppresses the transfer of phosphate from ATP to tyrosine residues in protein substrates by a tyrosine kinase [1]. Targets include membrane-associated receptor kinases and intracellular nonreceptor kinases involved in cellular signaling. Many inhibitors occupy the ATP-binding region, whereas others bind an allosteric site and stabilize a kinase conformation with reduced catalytic activity [1][2]. Binding can be reversible or involve covalent modification of an appropriately positioned amino acid residue [2]. Individual compounds differ in their recognition of kinase conformations and neighboring binding pockets, producing different selectivity profiles across related enzymes [1][2]. Gefitinib inhibits the epidermal growth factor receptor kinase, with particular receptor mutations associated with increased cellular sensitivity [3]. Conversely, changes in the inhibitor-binding region or amplification of the kinase gene can restore signaling despite drug exposure, as demonstrated for BCR–ABL and imatinib [4]. Reduced tyrosine phosphorylation therefore reflects both inhibitor–kinase binding and the molecular state of the targeted signaling system [1][4].